跳转至内容
Merck
CN

06-944

Sigma-Aldrich

抗-TPOR/c-Mpl抗体

Upstate®, from rabbit

别名:

Anti-C-MPL, Anti-MPLV, Anti-THCYT2, Anti-THPOR, Anti-TPOR

登录查看公司和协议定价

关于此项目

UNSPSC代码:
12352203
eCl@ss:
32160702
NACRES:
NA.41
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

生物来源

rabbit

质量水平

偶联物

unconjugated

抗体形式

purified antibody

抗体产品类型

primary antibodies

克隆

polyclonal

种属反应性

mouse, human

制造商/商品名称

Upstate®

技术

immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

同位素/亚型

IgG

NCBI登记号

UniProt登记号

运输

dry ice

靶向翻译后修饰

unmodified

基因信息

human ... MPL(4352)
mouse ... Mpl(17480)

一般描述

68.5 kDa(计算值)

免疫原

KLH偶联的合成肽,对应于人TPO(促血小板生成素)受体(C-ANHSYLPLSYWQQP)的氨基酸。

应用

抗-TPOR/c-Mpl抗体是一种抗TPOR/c-Mpl的抗体,用于IP、WB、IH。
研究子范畴
生长因子 & 受体
研究类别
信号传导

生化/生理作用

糖基化和非糖基化TPO受体/c-Mpl

外形

0.1M Tris-甘氨酸,pH 7.4,0.15M NaCl,0.05%叠氮化钠,然后添加甘油至30%
形式:纯化
蛋白A层析

制备说明

在-20°C下可保存2年

分析说明

通过免疫印迹对DAMI细胞的RIPA裂解液进行了常规评估

法律信息

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

免责声明

除非我们的产品目录或产品附带的其他公司文档另有说明,否则我们的产品仅供研究使用,不得用于任何其他目的,包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。

未找到合适的产品?  

试试我们的产品选型工具.

储存分类代码

10 - Combustible liquids

WGK

WGK 1


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Melanie Märklin et al.
Journal of cellular and molecular medicine, 24(21), 12491-12503 (2020-09-22)
Thrombocyte formation from megakaryocyte and their progenitor cells is tightly regulated by thrombopoietin (TPO) and its receptor c-MPL, thereby maintaining physiological functionality and numbers of circulating platelets. In patients, dysfunction of this regulation could cause thrombocytopenia or myeloproliferative syndromes. Since
Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression.
Sugita, M; Kalota, A; Gewirtz, AM; Carroll, M
Leukemia null
Norma E Fox et al.
Experimental hematology, 37(4), 495-503 (2009-03-24)
To genetically and functionally characterize mutations of c-Mpl that lead to thrombocytopenia in a child with congenital amegakaryocytic thrombocytopenia. We identified two c-Mpl mutations in a child with clinical features of congenital amegakaryocytic thrombocytopenia, one a previously described mutation in
A R Moliterno et al.
Blood, 94(8), 2555-2561 (1999-10-09)
Recently, we demonstrated a marked reduction in the expression of the thrombopoietin receptor, Mpl, in polycythemia vera (PV) platelets and megakaryocytes using an antiserum against the Mpl extracellular domain. To further examine this abnormality, we raised an antibody to the
Cédric Cleyrat et al.
Traffic (Copenhagen, Denmark), 15(9), 961-982 (2014-06-17)
Myeloproliferative neoplasms (MPNs) are often characterized by JAK2 or calreticulin (CALR) mutations, indicating aberrant trafficking in pathogenesis. This study focuses on Mpl trafficking and Jak2 association using two model systems: human erythroleukemia cells (HEL; JAK2V617F) and K562 myeloid leukemia cells

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持